Takeda Pharmaceutical
311 hedge funds and large institutions have $1.9B invested in Takeda Pharmaceutical in 2020 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 90 increasing their positions, 90 reducing their positions, and 34 closing their positions.
9% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 34
1% more funds holding
Funds holding: 309 → 311 (+2)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 90
0.26% less ownership
Funds ownership: 7.08% → 6.82% (-0.26%)
4% less capital invested
Capital invested by funds: $1.98B → $1.9B (-$78.4M)
14% less call options, than puts
Call options by funds: $54M | Put options by funds: $63.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$21.1M |
| 2 |
Goldman Sachs
New York
|
+$12.1M |
| 3 |
GCM
Glenview Capital Management
New York
|
+$10.8M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$7.82M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$6.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$25M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$18.3M |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$16.5M |
| 4 |
AC
Adelphi Capital
London,
United Kingdom
|
-$16.1M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$13.3M |
TAK Hedge Fund Activity: Q3 2020 in Review
311 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2020, worth a combined $1.9B — down 4% from $1.98B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new TAK positions and 34 closed out — a net gain of 3 holders — while 90 added to existing stakes and 90 trimmed.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $21.1M. The largest seller was First Trust Advisors, exiting entirely with an estimated $25M sold.
- 311 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2020, up from 309 in Q2 2020.
- Funds reported $1.9B of Takeda Pharmaceutical stock for Q3 2020, down 4% quarter-over-quarter.
- 37 funds opened new Takeda Pharmaceutical positions in Q3 2020 and 34 closed out, a net change of +3 holders.
- The largest Takeda Pharmaceutical buyer in Q3 2020 was ARK Investment Management, an estimated $21.1M added.
- The largest Takeda Pharmaceutical seller in Q3 2020 was First Trust Advisors, an estimated $25M sold.
Based on aggregated 13F filings for Q3 2020.